FXIIa-IN-4
FXIIa-IN-4 (compound 22) is a potent, selective human FXIIa inhibitor with the IC50 of 0.032 μM, 0.30 μM, > 50 μM for FXIIa, thrombin and FXIa, respectively. FXIIa-IN-4 can be used for study of anticoagulant[1].
Product Specifications
UNSPSC
12352005
Target
Factor Xa; Thrombin
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/fxiia-in-4.html
Concentration
10mM
Purity
98.87
Solubility
DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(C1=NN(C(C2=CC=C(F)C=C2)=O)C(N)=N1)OC
Molecular Formula
C11H9FN4O3
Molecular Weight
264.21
References & Citations
[1]Ma’Lik D. Woodland, et al. New Triazole-Based Potent Inhibitors of Human Factor XIIa as Anticoagulants. ACS Omega 2024, 9, 9, 10694–10708.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Lentiviral mouse Hivep3 shRNA (UAS) - Lentiviral mouse Hivep3 shRNA (UAS) plasmid
TSSK2 (Testis-specific Serine/threonine-protein Kinase 2, TSSK-2, Testis-specific Kinase 2, TSK2, TSK-2, DiGeorge Syndrome Protein G, DGSG, DGS-G, Serine/threonine-protein Kinase 22B, STK22B, SPOGA2) (MaxLight 490)
TSSK2 (Testis-specific Serine/threonine-protein Kinase 2, TSSK-2, Testis-specific Kinase 2, TSK2, TSK-2, DiGeorge Syndrome Protein G, DGSG, DGS-G, Serine/threonine-protein Kinase 22B, STK22B, SPOGA2) (MaxLight 490)